» Articles » PMID: 28178697

Obesity and Kidney Disease: Hidden Consequences of the Epidemic

Overview
Journal Am J Nephrol
Publisher Karger
Specialty Nephrology
Date 2017 Feb 9
PMID 28178697
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by 40% in the next decade. This increasing prevalence has implications for the risk of diabetes, cardiovascular disease, and also for chronic kidney disease. A high body mass index is one of the strongest risk factors for new-onset chronic kidney disease. In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased body weight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing chronic kidney disease in the long-term. The incidence of obesity-related glomerulopathy has increased 10-fold in recent years. Obesity has also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including kidney cancer. This year, the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that make preventive behaviors an affordable option.

Citing Articles

Atherogenic index of plasma and obesity-related risk of stroke in middle-aged and older Chinese adults: a national prospective cohort study.

Zhai L, Huo R, Zuo Y Diabetol Metab Syndr. 2024; 16(1):245.

PMID: 39380102 PMC: 11462917. DOI: 10.1186/s13098-024-01481-y.


Towards an adiposity-related disease framework for the diagnosis and management of obesities.

Perdomo C, Aviles-Olmos I, Dicker D, Fruhbeck G Rev Endocr Metab Disord. 2023; 24(5):795-807.

PMID: 37162651 PMC: 10492748. DOI: 10.1007/s11154-023-09797-2.


Association of physical activity and heart rate variability in people with overweight and obesity: A systematic review.

Sinha M, K V, Maiya A, K N S, U S, Shankar N R F1000Res. 2023; 12:156.

PMID: 36875496 PMC: 9982191. DOI: 10.12688/f1000research.124707.1.


Adiponectin Paradox More Evident in Non-Obese Than in Obese Patients with Diabetic Microvascular Complications.

Satoh K, Nagasawa K, Takebe N, Kinno H, Shozushima M, Onodera K Diabetes Metab Syndr Obes. 2023; 16:201-212.

PMID: 36760589 PMC: 9882416. DOI: 10.2147/DMSO.S387744.


Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease.

Larkin B, Nguyen L, Hou M, Glastras S, Chen H, Faiz A Diabetes Obes Metab. 2022; 24(10):1939-1949.

PMID: 35635331 PMC: 9544807. DOI: 10.1111/dom.14778.